Expectations of Patients in Palliative Situation
NCT06786897 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 37
Last updated 2025-01-22
Summary
To date, there is a lack of data about the benefit of blood cell transfusions for patients diagnosed of a hematologic malignancy who are not eligible for curative treatments. Furthermore, there is no clear guideline about how to transfuse these patients and when the blood cell transfusions should be stopped.
Allogenic stem cell transplantation is nowadays the only curative treatment for patients with high-risk myeloid neoplasms. Knowing that the median age at diagnostic for acute myeloid leukemia is 68 years and this incidence increases after 65 years, a lot of patients won't be eligible for allogenic stem cell transplantation.
Besides, patients with haematologic malignancies are prone to cytopenias, due to their pathology and the treatments used to limit its progression. A study estimate that these patients need a median of 4 blood cell units per month, and it is known that repeated transfusions are associated with an increased risk of dying in hospital.
Finally, it is estimate that there was a lack of 20 000 blood cell units in France in 2022.
It therefore seems essential to find ways to optimize blood transfusion prescriptions in this population of patients who won't be eligible for curative treatments, with the main idea of maintaining or even improving their quality of life.
The investigators will study the expectations of patients in palliative situation, paramedics and medical staff concerning blood cell transfusions, by asking them if whether or not they believe that the transfusion planed to be administer will benefit the patient. To do this, investigators will distribute questionnaires before each blood cell transfusions to patients who will be included, to the paramedic who administered the transfusion and to the physician who prescribed the transfusion.
It is to investigators knowledge the first study to compare the expectations of patients in palliative situation, paramedics and medical staff concerning blood cell transfusions in hematology department, and follow the evolution of these expectations prospectively.
Conditions
Interventions
- OTHER
-
Questionnaire and Physical Exam
Questionnaires evaluating the expectations of patients in palliative situation, of paramedics and medical staff, concerning blood cell transfusions.
Sponsors & Collaborators
-
University Hospital, Montpellier
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-02-01
- Primary Completion
- 2027-01-01
- Completion
- 2028-01-01
Countries
- France
Study Locations
More Related Trials
-
The Efficacy of Allo-HSCT in ND HR-CBF-AML
NCT06458244 ·Status: RECRUITING
-
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
NCT05237258 ·Status: RECRUITING ·Phase: NA
-
The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia
NCT06458257 ·Status: RECRUITING
-
Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML
NCT02888522 ·Status: UNKNOWN
-
Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia
NCT02844257 ·Status: COMPLETED
-
A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia
NCT04822766 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)
NCT01146977 ·Status: UNKNOWN ·Phase: PHASE2
-
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
NCT01326728 ·Status: TERMINATED
-
A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia
NCT00400673 ·Status: COMPLETED ·Phase: PHASE2
-
Enhanced Palliative Care in MDS and AML
NCT04226768 ·Status: UNKNOWN ·Phase: NA
-
AML Therapy With Irradiated Allogeneic Cells
NCT02105116 ·Status: TERMINATED ·Phase: NA
-
A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia
NCT02975869 ·Status: COMPLETED ·Phase: NA
-
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
NCT04777916 ·Status: RECRUITING
-
A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy
NCT03310918 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma
NCT00781170 ·Status: COMPLETED ·Phase: PHASE2
-
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
NCT00274846 ·Status: COMPLETED ·Phase: PHASE2
-
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
NCT00303667 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
NCT01801046 ·Status: TERMINATED ·Phase: PHASE1
-
An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT05577611 ·Status: UNKNOWN ·Phase: PHASE1
-
Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation
NCT03964922 ·Status: UNKNOWN ·Phase: NA
-
Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and Survival
NCT01188330 ·Status: UNKNOWN ·Phase: NA
-
Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
NCT00322101 ·Status: COMPLETED ·Phase: PHASE3
-
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
NCT02441803 ·Status: COMPLETED ·Phase: PHASE2
-
Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT
NCT03715621 ·Status: UNKNOWN
-
Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
NCT03659084 ·Status: UNKNOWN